Note: Descriptions are shown in the official language in which they were submitted.
CA 02592041 2007-06-20
WO 2006/068685 PCT/US2005/036224
FLUOROPOLYMERS HAVING PENDANT
AlVIIDOXIlVIE OR AMIDRAZONE STRUCTURES
TECHNICAL FIELD
This invention relates to fluoropolymers having pendant amidoxime groups,
pendant amidrazone groups, or combinations thereof. The invention also relates
to
methods of making, and articles containing, such fluoropolymers.
BACKGROUND
Fluorine-containing polymers (i.e., "fluoropolymers") are a commercially
useful
class of materials. Fluoropolymers include, e.g., crosslinked
fluoroelastomers,
uncrosslinked fluoroelastomer gums, and semi-crystalline fluoroplastics.
Generally,
fluoroelastomers exhibit significant tolerance to high temperatures and to
harsh chemical
environments. Consequently, they are particularly well adapted for use as
seals, gaskets,
0-rings, and other molded parts in systems that are exposed to elevated
temperatures
and/or harsh chemicals. Such parts are widely used in the chemical processing,
semiconductor, aerospace, and petroleum industries, among others.
Fluoroelastomers often include a cure-site component to facilitate cure in the
presence of a catalyst. One class of useful cure-site components includes
nitrile group-
containing monomers, which, in the presence of catalysts, form triazines.
These cure-
catalysts are typically organotin catalysts, ammonium salts, or ammonia-
generating
compounds. Such catalysts, however, may be toxic, and/or may release
considerable
amounts of ions such as undesirable extractable metal residues in the cured
materials.
SUMMARY
In one aspect, the present invention relates to a fluoropolymer comprising
first
interpolymerized cure site units, wherein the cure site units have at least
one pendant
amidoxime group, pendant amidrazone group, or combinations thereof. In some
embodiments, the fluoropolyrner comprises interpolymerized units derived from
at least
one monomer selected from tetrafluoroethylene, chlorotrifluoroethylene, CF2=CF-
Rfl,
2 2 , CF2=CF-CFX-O-Rf , and CH2=CR2, wherein Rf l is a perhaloalkyl, Rf is
CF2=CF-O-Rf
-1-
CA 02592041 2007-06-20
WO 2006/068685 PCT/US2005/036224
2
perhaloalkyl or a perhaloalkoxyalkyl, X is F or R f, and each R is
independently selected
from the group consisting of hydrogen, a halogen, or an aliphatic group;
wherein the
aliphatic group(s) may have one or more halogen substituent(s).
In another aspect, the present invention relates to a fluoropolymer comprising
first
interpolymerized cure site units, wherein the cure site units have at least
one pendant
amidoxime group, pendant amidrazone group, or combinations thereof; and second
interpolymerized cure site units. In some embodiments, the second
interpolymerized cure
site units have a reactive group selected from a nitrile group, an imidate
group, a
pentafluorophenoxy group, bromine, iodine, and combinations thereof. In some
embodiments, the molar ratio of the first interpolymerized cure site units to
the second
interpolymerized cure site units is between about 0.25 and about 4.
In another aspect, the present invention provides an article comprising a
fluoropolymer comprising first interpolymerized cure site units, wherein the
cure site units
have at least one pendant amidoxime group, pendant amidrazone group, or
combinations
thereof. In some embodiments, the article is a hose, a hose lining, a seal, a
gasket, or an
0-ring. In some embodiments, the fluoropolymer is at least partially cured.
In another aspect, the present invention provides a method of making an
article
comprising providing a fluoropolymer comprising first interpolymerized cure
site units,
wherein the cure site units have at least one pendant amidoxime group, pendant
amidrazone group, or combinations thereof, shaping the fluoropolymer, and
optionally
curing the shaped fluoropolymer.
In yet another aspect, the present invention provides a method of making a
fluoropolymer having interpolymerized cure site units, wherein the cure site
units have at
least one pendant amidoxime group, pendant amidrazone group, or combinations
thereof.
In some embodiments, the method comprises (i) providing a fluoropolymer having
one or
more interpolymerized units having a reactive group; and (ii) converting at
least reactive
group into a pendant amidoxime and/or pendant amidrazone group. In some
embodiments, the reactive group is a nitrile group. In some embodiments, the
conversion
of the reactive group is carried out in the presence of a swelling agent. In
some
embodiments, the method comprises (i) providing a cure site monomer having
pendant
amidoxime group(s), pendant amidrazone group(s), a salt thereof, or
combinations thereof;
and (ii) copolymerizing the cure site monomer with at least one monomer
selected from
-2-
CA 02592041 2007-06-20
WO 2006/068685 PCT/US2005/036224
tetrafluoroethylene, chlorotrifluoroethylene, CF2=CF-Rf1, CF2=CF-O-Rf , CF2=CF-
2 2
, and CH2=CR2, wherein Rfl is a perhaloalkyl, Rf is perhaloalkyl or a
CFX-O-Rf
perhaloalkoxyalkyl, X is F or R f, and each R is independently selected from
the group
consisting of hydrogen, a halogen, or an aliphatic group; wherein the
aliphatic group(s)
may have one or more halogen substituent(s).
The above summary of the present invention is not intended to describe each
embodiment of the present invention. The details of one or more embodiments of
the
invention are also set forth in the description below. Other features,
objects, and
advantages of the invention will be apparent from the description and from the
claims.
DETAILED DESCRIPTION
The present invention includes fluoropolymers comprising interpolymerized cure
site units having one or more pendant amidoxime groups, pendant amidrazone
groups, or
combinations thereof.
In some embodiments, fluoropolymers of the present invention include
interpolymerized units derived from one or more principal monomers, and, in
some
embodirnents, at least two principal monomers. Examples of suitable principal
monomers
include perfluoroolefins (e.g., tetrafluoroethylene (TFE) and
hexafluoropropylene (HFP)),
halo-substituted fluoroolefins (e.g., chlorotrifluoroethylene (CTFE)),
perhalovinyl ethers
(e.g., perfluorovinyl ethers), perhaloallyl ethers (e.g., perfluoroallyl
ethers), and hydrogen-
containing monomers including, e.g., non-fluorinated olefins (e.g., ethylene,
propylene,
and the like) and partially-fluorinated, hydrogen-containing monomers (e.g.,
partially-
fluorinated olefins, vinylidene fluoride (VDF) and vinyl fluoride).
In some embodiments, the fluoropolymer composition may include
interpolymerized units derived from one or more ethylenically-unsaturated
monomers
represented by the formulas CF2=CF-Rf1, CFZ=CF-O-Rf , CFZ=CF-CFX-O-Rf , and
2
is perhaloalkyl or a perhaloalkoxyalkyl, X is
CH2=CR2, wherein Rf1 is a perhaloalkyl, Rf
F or Rf , and each R is independently selected from the group consisting of
hydrogen, a
halogen (e.g., Cl or F), or an aliphatic group; wherein the aliphatic group(s)
may have one
or more halogen substituent(s). In some embodiments, Rfl and/or Rf are
perfluorinated.
In some embodiments, Rf1 is a perhaloalkyl containing 1-8 carbon atom(s). In
some
-3-
CA 02592041 2007-06-20
WO 2006/068685 PCT/US2005/036224
embodiments, Rf is a perhaloalkyl or a perhaloalkoxyalkyl containing 1-8
carbon atom(s).
In some embodiments, the fluoropolymer composition may include
interpolymerized units
derived from perfluorinated vinyl ethers including perfluoroalkyl vinyl
ether(s) (PAVE)
and perfluoroalkoxy vinyl ether(s) (PAOVE).
Suitable perfluorinated vinyl ethers include those of Formula 1:
CFa=CFO(R'tO)a(R"fO)bRii. f (1)
wherein R' f and R"f are the same or are different linear or branched
perfluoroalkylene
groups of 1-6 carbon atoms; and a and b are, independently, 0 or an integer
from 1 to 10.
In some embodiments, R"' f is a perfluoroalkyl of 1 to 8 carbon atoms(s), in
some
embodiments 1 to 4 carbon atom(s), or even one carbon atom. In some
embodiments, R"' f
is a perfluoroalkoxyalkyl of 1 to 15 carbon atom(s), in some embodiments, 1 to
8 carbon
atom(s), and even 1-3 carbon atoms.
In some embodiments, the composition includes repeating units derived from
perfluorinated vinyl ethers of Formula 2:
CF2=CFO(CF2CFXO)nRf (2)
wherein X is F or CF3; n is 0-5, and Rf is a perfluoroalkyl group of 1-8
carbon atom(s). In
some embodiments, the perfluoroalkyl vinyl ethers are those wherein n is 0 or
1, and Rf
contains 1-3 carbon atoms.
Other useful perfluorinated monomers include compounds of Formula 3:
CF2=CFO[(CF2)m(CFX)CO]dRf (3)
wherein Rf is a perfluoroalkyl group having 1-8 carbon atom(s), m is 1-5, c is
0-5, d is 0-5,
and X is F or CF3. In some embodiments, Rf is C3F7 or CF3, m is 1-2, c is 0-1,
d is 1, and
X = CF3.
Additional useful perfluorinated monomers include those of Formula 4:
CF2=CFO(CF2CF(CF3)O)g(CF2)kO(CF2)pCXF2X+1 (4)
wherein g is 0 or an integer from 1-10, k is an integer from 1-6, p is 0-3,
and x is 1-5. In
some embodiments, g is 0 or 1, k is 1-5, p is 0 or 1, and x is 1.
-4-
CA 02592041 2007-06-20
WO 2006/068685 PCT/US2005/036224
Additional perfluoroalkoxy vinyl ethers useful in the invention include those
of the
Formula 5:
CF2=CFO(CF2)t[CF(CF3)]uO(CF2O)WCXF2x+1 (5)
wherein t is 1-3, u is 0-1, w is 0-3, and x is 1-5, preferably 1.
Examples of perfluoroalkylvinyl ethers suitable for some embodiments of the
present invention include perfluoromethyl vinyl ether, perfluoroethyl vinyl
ether, and
perfluoropropyl vinyl ether. Examples of perfluoroalkoxyvinyl ethers suitable
for some
embodiments of the present invention include CF2=CFOCF2OCF2CF2CF3,
CF2=CFOCF2OCF2CF3, CF2=CFOCFZOCF3, CF2=CFO(CF2)30CF3, and
CF2-CFOCF2CF2OCF3. Combinations of these and other perfluoroalkyl vinyl ethers
and
perfluoroalkoxy vinyl ethers may also be employed.
One example of a useful fluoropolymer is composed of principal monomer units
of
tetrafluoroethylene and at least one perfluoroalkylvinyl ether. In some
embodiments, the
copolymerized perfluoroalkyl vinyl ether units constitute at least about 10
mol%, in some
embodiments, at least about 15 mol%, and, in some embodiments, at least about
30 mol%
of the total monomer units present in the polymer. In some embodiments, the
copolymerized perfluoroalkyl vinyl ether units constitute no greater than
about 45 mol%,
in some embodiments, no greater than about 40 mol%, and, in some embodiments,
no
greater than about 35 mol% of the total monomer units present in the polymer.
In some embodiments, fluoroelastomers of the present invention contain at
least 50
mol% of interpolymerized units derived from TFE, CTFE, or HFP. In some
embodiments,
the balance of the interpolymerized units is derived from vinylethers and cure
site
monomers.
In some embodiments, the fluoropolymers of the present invention may contain
interpolymerized units derived from one or more hydrogen-containing monomers,
which
may have halogen substituents (e.g., F or Cl). In some embodiments, partially
fluorinated
polymers of the present invention may contain 5-95 mol% units of VDF; 1-50
mol%
propylene and/or ethylene; 95-4 mol% units of TFE, CTFE and/or HFP; up to 35
mol%
units of vinyl ethers; and/or up to 5 mol% units of cure site monomers.
The polymers of the present invention comprise interpolymerized units having
one
or more pendant amidoxime structures (i.e., -C(NR2)=NOR and/or its tautomer -
C(NR-
-5-
CA 02592041 2007-06-20
WO 2006/068685 PCT/US2005/036224
OR)=NR), and/or pendant amidrazone stractures (i.e., -C(NR2)=N-NR2 and/or its
tautomer -C(NR-NR2)=NR), wherein each R is independently selected from the
group
consisting of hydrogen, and linear or branched, substituted or unsubstituted,
perfluorinated, partially-fluorinated, or non-fluorinated, alkyl or aryl
groups, optionally
containing one or more heteroatoms. In some embodiments, at least one R group
is
hydrogen. In some embodiments, all of the R groups are hydrogens.
In some embodiments, the amidoxime and/or amidrazone groups can be attached
directly to the polymer backbone. In some embodiments, one or more of the
amidoxime
and/or amidrazone groups may be indirectly attached to the backbone via a
substituted or
unsubstituted, linear or branched, aliphatic chain interposed between the
polymer
backbone and the amidoxime and/or amidrazone group. In some embodiments, the
amidoxime or amidrazone group is at the tenninal position of the aliphatic
group;
however, the amidoxime or amidrazone group may be present at any position
along the
aliphatic chain.
In some embodiments, the amidoxime and/or amidrazone groups are attached to
the polymer backbone via alkyl groups, e.g., B-(CZa)n A wherein, A is an
amidoxime or
amidrazone; B represents the polymer backbone; each Z is independently
selected from
hydrogen, a halogen (e.g., F or Cl), or an aliphatic group (in some
embodiments, an
aliphatic group containing 1-8 carbon atoms), which aliphatic group may have
halogen
substituents; and n = 1 to 50, in some embodiments, 1 to 20, or even 1 to 10.
In some
embodiments, the interposed alkyl chain is perfluorinated, in which case each
Z is F.
In some embodiments, the amidoxime and/or amidrazone groups can also be
attached by alkoxy side chains, e.g., B-(CZ2)õ(O-R2)m (O-R3)p-(CZ2)q CZX-A,
wherein
R2 and R3 are independently selected from C1-C10 (in some embodiments, C1-C5)
alkylenes, which may be linear or branched and which may be hydrogen-
containing,
partially-halogenated, partially-fluorinated, perhalogenated, or
perfluorinated; n and m are
each independently 1 to 50, in some embodiments, 1 to 20, or even 1 to 10; p
is 0 to 10; q
is 0 to 10; each Z is independently a hydrogen, a halogen (e.g., F, Cl, or
Br); and X is F or
CF3. In some embodiments, the alkoxy side chain is a perfluorinated alkoxy, in
which
case each Z is F, leading to, e.g., B-(OCF2)-(CF2)4-A.
-6-
CA 02592041 2007-06-20
WO 2006/068685 PCT/US2005/036224
In some embodiments, the amidoxime or amidrazone structure is located at the
terminal position of the alkyl or alkoxy side chain. In some embodiments, the
amidoxime
or amidrazone structure is located at any other position along the side chain.
In some
embodiments, the amidoxime or amidrazone structure is pendant to a branch on
the side
chain.
The level of amidoxime and/or amidrazone units in the overall fluoropolymer
composition is that amount sufficient to provide the desired physical
properties in a
selected material after curing. In some embodiments, the level of amidoxime
and/or
amidrazone units is at least about 0.01 mol%, in some embodiments, at least
about 0.1
mol%, in some embodiments, at least about 0.2 mol%, in some embodiments, at
least
about 0.5 mol%, or even at least about 0.7 mol%. In some embodiments, the
level of
amidoxime and/or amidrazone units is not greater than about 5 mol%, in some
embodiments, not greater than about 3 mol% and, in some embodiments, not
greater than
about 1 mol%.
The amidoxime and/or amidrazone units may be introduced into the polymer by
various means. In some embodiments, the amidoxime and/or amidrazone units are
introduced into the polymer by copolymerization of monomers having pendant
amidoxime
and/or amidrazone structures. In some embodiments, pendant functional groups
on the
polymer backbone are converted into amidoxime and/or amidrazone units by,
e.g.,
addition or substitution reactions.
Monomers having pendant amidoxime and/or amidrazone structures (e.g., a
perfluorovinyl ether having an amidoxime or amidrazone group) can be prepared
by a
variety of methods. For example, exemplary methods of preparing monomers
having
amidrazone groups are described in "The chemistry of amidines and imidates,"
(S. Patai,
Ed., John Wiley & Sons, Ltd., Vol. 1, pages 494-513 (1975)).
One method of preparing the desired monomers includes providing a monomer
having a reactive group, and converting the reactive group into an amidoxime,
an
amidrazone, or a salt thereof. For example, in some embodiments, the reactive
group can
be the nitrile functionality of a nitrile-containing vinyl ether (e.g.,
CF2=CF2-O-(CF)n CN;
n=1-10). In some embodiments, the nitrile group can be converted into an
amidoxime
structure by reacting a mixture (e.g., a 1:1 mixture) of vinyl ether and
alcohol (e.g.,
methanol) in the presence of hydroxylamine or a salt thereof, e.g., an aqueous
solution of
-7-
CA 02592041 2007-06-20
WO 2006/068685 PCT/US2005/036224
hydroxylamine or a salt thereof. Similarly, in some embodiments, the nitrile
group may be
converted into an amidrazone structure by reacting a mixture (e.g., a 1:1
mixture) of a
nitrile-containing vinyl ether and alcohol (e.g., methanol) in the presence of
hydrazine or
its salt, e.g., an aqueous solution of hydrazine or a salt thereof.
Alternatively, in some
embodiments, an amidoxime- or amidrazone-containing molecular fragment can be
grafted onto a monomer using conventional grafting techniques.
In some embodiments, it may be desirable to polymerize amidoxime- and/or
amidrazone-containing monomers, either as free amidoxime and/or amidrazones
(i.e., -
C(=N-OH)-NH2 ) or as a salt (e.g., -C(=N-OH)-NHZ-HX, wherein HX = HCI, or
another
organic or inorganic free acid), via, e.g., aqueous or solvent polymerization.
Solvent
polymerization may be done, e.g., in non-telogenic organic solvents, such as
haloperfluoro
liquids, e.g., FREON R113 or FC75. Any soluble radical initiator can be used
including,
e.g., azobisisobutyronitrile (AIBN), potassium persulfate (KPS), ammonium
persulfate
(APS), and bis perfluoroacyl peroxides of the formula:
RfC O~CRf
\O-O/
where Rf is a perfluoroalkyl or perfluoroalkoxyalkyl group. The polymerization
is
typically run at a temperature in the range of 25-80 C and at a pressure in
the range of 2-
15 bar.
In some embodiments, the amidoxime and/or amidrazone structure can be
introduced by converting nitrile-containing polymers into amidoxime and/or
amidrazones.
For example, the amidoxime and/or amidrazone can be introduced by reaction of
a
fluoropolymer containing repeat units derived from nitrile-containing cure
site monomers
with hydroxylamine or hydrazine (or salts thereof) to convert the nitrile
group to an
amidoxime or amidrazone, respectively. Alternatively, in some embodiments, an
amidoxime- or amidrazone-containing molecular fragment can be grafted onto a
polymer
using conventional grafting techniques.
Using the technique of converting an already present nitrile functional group
on a
polymer backbone, the more convenient aqueous emulsion polymerization for
preparing
the polymer can be used. In addition, the conversion step of converting
nitrile groups can
be carried out in the presence of a swelling agent such as those described
below.
-8-
CA 02592041 2007-06-20
WO 2006/068685 PCT/US2005/036224
In some embodiments, other functional groups (e.g., carboxyl groups, hydroxyl
groups, acyl halide groups, amide groups, and imidate groups) may be converted
into
amidoxime and/or amidrazone groups. In some embodiments, the functional group
is
converted directly into an amidoxime and/or amidrazone group. In some
embodiments,
the functional group is converted into a nitrile group, which is then
converted into an
amidoxime and/or amidrazone group.
In some embodiments, monomers having convertible functional groups may be
copolymerized to form the fluoropolymer backbone. Subsequently, the functional
groups
may be converted into amidoxime and/or amidrazone groups using any of a
variety of
techniques including those described above.
Nitrile containing fluoropolymers may be prepared by methods known in the art.
For example, the polymerization process can be carried out by free-radical
polymerization
of the monomers as emulsions in water. In some embodiments, polymerization in
an
aqueous emulsion may be preferred because of the rapid and nearly complete
conversion
of monomers, easy removal of the heat of polymerization, and ready isolation
of the
polymer. Emulsion polymerization typically involves polymerizing monomers in
an
aqueous medium in the presence of an inorganic free-radical initiator system,
such as
ammonium persulfate or potassium permanganate, and a surfactant or suspending
agent.
Additionally, nitrile groups can be introduced through selected chain transfer
agents like I-
(CF2)õCN, or by using a free-radical polymerization process carried out in the
presence of
a perfluorosulfinate such as CN-(CFa)n SO2M, where in the two preceding
formulas n is
an integer from 1 to 10, and, in some embodiments, 1 to 6; and wherein M
represents a
hydrogen atom or a cation with valence x, which is 1 or 2.
The amidoxime and/or amidrazone groups are preferably introduced by converting
nitrile (-C=N) groups in selected polymers into amidoxime and/or amidrazone
groups.
The preferred conversion route of nitrile containing fluoropolymers involves
the reaction
of nitriles in the presence of an alcohol component and suitable hydroxylamine
or
hydrazine at ambient temperatures.
In the case of perfluoroelastomers, at least one swelling agent may be added
to the
polymers. Such swelling agent(s), which support interaction between
interfaces, can be a
partially fluorinated compound such as a hydrofluoroether (HFE), (e.g.,
NovecTM
Engineered Fluid HFE-7100 or 7200, commercially available from 3M Company, St.
Paul,
-9-
CA 02592041 2007-06-20
WO 2006/068685 PCT/US2005/036224
Minnesota), or any other fluorine containing liquid, e.g., FC 75 (FluorinertTM
fluorocarbon
solvent, also available from 3M Company). The conversion of the polymer
pendant nitrile
groups may be performed at room temperature or at higher temperatures (e.g.,
100 C). In
general, any fluorine containing inert liquid or any fluorine containing
alkanol with a
boiling point of at least about 40 C, and in some embodiments, at least about
50 C can
be used. In the case of non-perfluorinated elastomers, a swelling agent also
can be used.
Exemplary swelling agents include alcohols, inert hydrocarbon solvents, and
fluorinated
compounds.
To convert the nitrile group(s), the mixture of polymer, swelling agent,
alcohol,
and hydroxylamine or hydrazine is normally refluxed, although the reaction
proceeds at
room temperature. In some embodiments, the hydroxylamine or hydrazine may be
added
as a salt. In some embodiments, the hydroxylamine or hydrazine may be added as
an
aqueous solution. Generally, the swelling agent and the alcohol are used to
create a single-
phase including the hydroxylamine and/or hydrazine, which swells the solid
fluoropolymer. Generally, the amount of swelling agent and alcohol are not
critical.
The amount of hydroxylamine and/or liydrazine may be selected based upon the
desired conversion rate. In some embodiments, at least about 50% of the
nitrile groups are
converted into amidoxime and/or amidrazone functions, in some embodiments, at
least
about 60% of the nitrile groups, and in some embodiments, at least about 80%
of the
nitriles groups are converted. In some embodiments, substantially all of the
nitrile groups
are converted into amidoxime and/or amidrazone groups (e.g., greater than 90%,
and in
some embodiments, greater than 95%, or even greater than 99% of the nitrile
groups are
converted).
Complete conversion of the reactive groups (e.g., nitrile groups) to amidoxime
and/or amidrazone groups is not necessary. For example, in some embodiments
the ratio
of unconverted reactive groups to amidoxime and/or amidrazone groups is
greater than
about 0.1, in some embodiments, greater than about 0.25, in some embodiments,
greater
than about 0.5, or even greater than about 0.9. In some embodiments the ratio
of
unconverted reactive groups to amidoxime and/or amidrazone groups is less than
about 10,
in some embodiments, less than about 5, in some embodiments, less than about
4, in some
embodiments, less than about 2, or even less than about 1.1.
-10-
CA 02592041 2007-06-20
WO 2006/068685 PCT/US2005/036224
Generally, following conversion the polymer is isolated as a solid after
removing
the swelling agent and any solvents (e.g., alcohol) by, e.g., rinsing and
drying (e.g., drying
under vacuum).
In some embodiments, fluoropolymers comprising pendant amidoxime and/or
pendant amidrazone groups are self-curable (i.e., the fluoropolymer may be
cured even in
the absence of added curatives and/or crosslinking agents). In some
embodiments, heating
the curable material to an elevated temperature cures the fluoropolymer
compositions.
The fluoropolymer can also have interpolymerized cure site units having
reactive
groups other than the inventive amidoxime and/or amidrazone groups. For
example, in
some embodiments, the fluoropolymer can have nitrile groups or imidate groups.
In some
embodiments, nitrile groups may be introduced, e.g., by copolymerization of
well known
nitrile-containing vinylethers, such as CF2=CFO(CF2)LCN;
CF2=CFO(CF2)uOCF(CF3)CN; CF2=CF[OCF2CF(CF3)]rO(CF2)tCN; and
CF2=CFO[CF2CF(CF3)O]q(CF2O)yCF(CF3)CN, where L=2-12; u=2-6; r=1-2; t=1-4; q=0-
4; and y=0-6. Representative examples of such monomers include
CF2=CFO(CF2)3OCF(CF3)CN, perfluoro(8-cyano-5-methyl-3,6-dioxa-l-octene), and
CF2=CFO(CF2)5CN.
In some embodiments, the cure site monomer may include a pentafluorophenoxy
group as described, e.g., in U.S. Patent Nos. 3,467,638 and 3,682,872.
In some embodiments, the fluoropolymer can contain interpolymerized units
derived from a monomer a halogen that is capable of participation in a
peroxide cure
reaction as a reactive group. Such a halogen may be present along a
fluoropolymer chain
and/or in a terminal position. In some embodiments, the halogen is bromine or
iodine.
Copolymerization is preferred to introduce the halogen in a position along a
fluoropolymer
chain. In this route, a selection of the fluoropolymer components mentioned
above is
combined with a suitable fluorinated cure site monomer. Such a monomer can be
selected, for example, from the general formula Z-Rf-O,,-CF=CF2, wherein Z is
Br or I; Rf
is a substituted or unsubstituted C1-C12 fluoroalkylene, which may be
perfluorinated and
which may contain one or more ether oxygen atoms; and x is 0 or 1. Exemplary
cure site
monomers include the bromo- or iodo- fluorolefins including
bromodifluoroethylene,
bromotrifluoroethylene, iodotrifluoroethylene, 1-bromo-2,2-difluoroethylene,
and 4-
-11-
CA 02592041 2007-06-20
WO 2006/068685 PCT/US2005/036224
bromo-3,3,4,4-tetrafluorobutene-1, BrCF2OCF=CF2, BrCF2CF2OCF=CF2,
BrCF2CF2CF2OCF=CF2, CF3CF(Br)CF2OCF=CF2, and the like. In addition, non-
fluorinated bromo- or iodo- olefins, e.g., vinyl bromide and 4-bromo-l-butene,
can be
used.
In some embodiments, the amount of these additional interpolymerized cure site
units is at least about 0.01, in some embodiments, at least about 0.1 mol %.
In some
embodiments, the amount of these additional cure site monomers is not greater
than about
5 mol%, in some embodiments, not greater than about 3 mol%. In some
embodiments, the
molar ratio of interpolymerized cure site units having at least one pendant
amidoxime
group, pendant amidrazone group, or combinations thereof (i.e., the "first"
interpolymerized cure site units) to interpolymerized cure site units having
reactive groups
other than the inventive amidoxime and/or amidrazone groups (i.e., the
"second"
interpolymerized cure site units) is greater than about 0.1, in some
embodiments, greater
than about 0.25, in some embodiments, greater than about 0.5, or even greater
than about
0.9. In some embodiments the ratio of first interpolymerized cure site units
to second
interpolymerized cure site units is less than about 10, in some embodiments,
less than
about 5, in some embodiments, less than about 4, in some embodiments, less
than about 3,
or even less than about 1.1.
In some embodiments, second interpolymerized cure site units may comprise
unreacted groups, i.e., reactive groups that were not converted into amidoxime
and/or
amidrazone groups.
In some embodiments, the fluoropolymers can be cured using one or more
peroxide curatives. Suitable peroxide curatives generally include those that
generate free
radicals at curing temperatures. In some embodiments, dialkyl peroxide and
bis(dialkyl
peroxide), each of which decomposes at a temperature above 50 C, are
especially
preferred. In some embodiments, it is preferred to use a di-tertiarybutyl
peroxide having a
tertiary carbon atom attached to peroxy oxygen atom. Among the most useful
peroxides
of this type are 2,5-dimethyl-2,5-di(tertiarybutylperoxy)hex-3-yne and 2,5-
dimethyl-2,5-
di(tertiarybutylperoxy)hexane. Other peroxides can be selected from such
compounds as
dicumyl peroxide, dibenzoyl peroxide, tertiarybutyl perbenzoate, a,a'-bis(t-
butylperoxy-
diisopropylbenzene), and di[1,3-dimethyl-3-(t-butylperoxy)-butyl]carbonate. In
some
embodiments, about 1 to 3 parts of peroxide per 100 parts of fluoropolymer
(phr) is used.
-12-
CA 02592041 2007-06-20
WO 2006/068685 PCT/US2005/036224
In some embodiments, the fluoropolymer compositions can be cured using
divalent
metal amine complex catalysts, alone or in various combinations, as described
in U.S.
Patent Nos. 6,657,012 and 6,657,013. Such divalent metal amine complex
compounds are
represented by the general formula:
(CHNU~N M-'N N \ 2X
(CHz~.-'
wherein M is a divalent metal, X is an anionic group, and n is 2 to 8, in some
embodiments, 3 to 6, and even 3 or 5. Examples of suitable divalent metals
include
magnesium, nickel, zinc, cobalt, lead, iron, tin, cadmium, and calcium, with
magnesium
and zinc being preferred. Examples of suitable anionic groups include halide
(e.g.,
chloride, bromide, or iodide), hydroxylate, alkoxylate, carboxylate,
phenoxide, sulfonate,
sulfate, sulfite, carbonate, and nitrate groups, with halides such as
chlorides being
preferred. This formula includes, for example, complexes of 1,8-
diazabicyclo[5,4,0]undec-7-ene (DBU) and 1,5-diazabicyclo[4,3,0]non-5-ene
(DBN).
These complexes may be prepared, for example, by reacting DBU or DBN with a
metal
salt (e.g., a metal halide) in an organic solvent such as methanol or acetone
according to
the procedure described in U.S. Patent No. 4,833,212. In some embodiments,
more than
one such complex can be used.
Other suitable catalysts include those described in U.S. Patent Publications
US20020177666; and US 20020145228 (both allowed).
In some embodiments, the amount of curative is at least about 0.01 parts per
hundred parts fluoropolymer (phr), and, in some embodiments, at least about
0.5 phr. In
some embodiments, the amount of curative is not greater than about 10 phr, in
some
embodiments, not greater than 5 phr, and, in some embodiments, not greater
than 3 phr.
The fluoropolymer compositions can include any of the adjuvants commonly
employed in curable fluoropolymer formulations. For example, one material
often
blended with a fluoropolymer composition as a part of the peroxide curative
system, is a
coagent (sometimes also referred to as a co-curative) composed of a
polyunsaturated
-13-
CA 02592041 2007-06-20
WO 2006/068685 PCT/US2005/036224
compound that is capable of cooperating with the curative to provide a useful
cure. These
coagents can generally be added in an amount equal to between 0.1 and 10 parts
coagent
per hundred parts fluoropolymer (phr), preferably between 1 and 5 phr.
Examples of
useful coagents include triallyl cyanurate; triallyl isocyanurate;
tri(methylallyl)isocyanurate; tris(diallylamine)-s-triazine; triallyl
phosphite; N,N-diallyl
acrylamide; hexaallyl phosphoramide; N,N,N',N'-tetraalkyl tetraphthalamide;
N,N,N',N'-
tetraallyl malonamide; trivinyl isocyanurate; 2,4,6-trivinyl
methyltrisiloxane; and tri(5-
norbomene-2-methylene)cyanurate. Particularly useful is triallyl isocyanurate.
Other
useful coagents include the bis-olefins disclosed in EP 0 661 304 Al, EP 0 784
064 Al, EP
0 769 521 Al, and U.S. Patent No. 5,585,449.
The fluoropolymer compositions can also be cured by using other types of
curatives along with the integral amidoxime and/or amidrazone when the
undesirable
features of the known curing system are tolerable. Examples of such curatives
are known
and include bis-aminophenols (e.g., as described in U.S. Patent Nos. 5,767,204
and
5,700,879), bis-amidooximes (e.g., as described in U.S. Patent No. 5,621,145),
and
ammonium salts (e.g., as described in U.S. Patent No. 5,565,512).
Organometallic
compounds of arsenic, antimony, and tin also can be used; for example, as
described in
U.S. Patent Nos. 4,281,092; and 5,554,680. Particular examples include allyl-,
propargyl-,
allenyl-, tetraphenyl-, and triphenyl-tin hydroxide.
In addition, the integral amidoxime and/or amidrazone cure system can be
modified by a variety of methods. For example, ammonia-generating compounds
may be
included to modify the rate of cure of a particular composition, although such
modification
may also remove one or more advantages of the present invention. Such ammonia-
generating compounds are typically solid or liquid at ambient conditions, and
then
generate ammonia under conditions of cure. These compounds include, for
example,
hexamethylene tetramine (urotropin) and dicyandiamide, as well as metal-
containing
compounds and triazine derivatives. More detail regarding such ammonia-
generating
compounds is found in U.S. Patent No. 6,281,296.
It may be advantageous for tailoring processing properties and final end
properties
to add one or more onium salts to the fluoropolymer compositions. Examples of
suitable
onium salts are described in U.S. Patent No. 4,882,390. Specific examples
include
-14-
CA 02592041 2007-06-20
WO 2006/068685 PCT/US2005/036224
triphenylbenzyl phosphonium chloride, tributyl alkyl phosphonium chloride,
tributyl
benzyl ammonium chloride, tetrabutyl ammonium bromide, and triarylsulfonium
chloride.
Additives, such as stabilizers, plasticizers, lubricants, fillers, and
processing aids
typically utilized in fluoropolymer compounding, can be incorporated into the
compositions, provided they have adequate stability for the intended service
conditions.
In particular, low temperature performance can be enhanced by incorporation of
perfluoropolyethers. See, e.g., U.S. Patent No. 5,268,405; 6,255,536; and
6,294,627.
Carbon black fillers are typically also employed in fluoropolymers as a means
to
balance modulus, tensile strength, elongation, hardness, abrasion resistance,
conductivity,
and processability of the compositions. Suitable examples include MT blacks
(medium
thermal black) designated N-991, N-990, N-908, and N-907; FEF N-550; and large
particle size farnace blacks. When large size particle black is used, 1 to 70
parts filler per
hundred parts fluoropolymer (phr) is generally sufficient.
Fluoropolymer fillers may also be present in the curable compositions.
Generally,
from 1 to 50 phr of fluoropolymer filler is used. The fluoropolymer filler can
be finely
divided and easily dispersed as a solid at the highest temperature used in
fabrication and
curing of the inventive composition. By solid, it is meant that the filler
material, if
partially crystalline, will have a crystalline melting temperature above the
processing
temperature(s) of the curable composition(s). The preferred way to incorporate
fluoropolymer filler is by blending latices. This procedure, including various
kinds of
fluoropolymer filler, is described in U.S. Patent No. 6,720,360.
One or more acid acceptors can also be added to the formulations. However,
where the presence of extractable metallic compounds is undesirable (such as
for
semiconductor applications), the use of inorganic acid acceptors should be
minimized, and
preferably avoided altogether. Commonly used acid acceptors include, for
example, zinc
oxide, calcium hydroxide, calcium carbonate, magnesium oxide, etc. These
compounds
generally are used in the fluoropolymer formulation to bind any HF or other
acids that
might be generated at the high temperatures where the fluoropolymers are
intended to
function.
The curable fluoropolymer compositions of the invention may also be combined
with other curable fluoropolymer compositions such as peroxide-curable
fluoropolymer
compositions. These additional curable fluoropolymer compositions typically
employ
-15-
CA 02592041 2007-06-20
WO 2006/068685 PCT/US2005/036224
small amounts of cure site monomers as a comonomer. Suitable cure site
monomers are
those which, when combined with a curative (e.g., a peroxide), and preferably
a coagent,
will provide a cured composition. Preferably, these cure site monomers include
at least
one halo group (e.g., a bromo or an iodo group).
The curable fluoropolymer compositions can be prepared by mixing the
fluoropolymer, and, optionally, catalyst(s), additive(s), additional
curative(s), and other
adjuvant(s), if any, in conventional rubber processing equipment. The desired
amounts of
compounding ingredients and other conventional adjuvants or ingredients can be
added to
the curable fluorocarbon gum stock and intimately admixed or compounded
therewith by
employing any of the usual rubber mixing devices such as internal mixers,
(e.g., Banbury
mixers), roll mills, or any other convenient mixing device. In some
embodiments, the
temperature of the mixture during the mixing process should not rise above
about 120 C.
In some embodiments, it is preferable to distribute the components and
adjuvants
uniformly throughout the gum during mixing for effective cure.
In some embodiments, the mixture is then processed and shaped (e.g., in the
shape
of a hose or hose lining, a seal, a gasket, or an 0-ring seal) by, e.g.,
extrusion or molding.
In some embodiments, the shaped article can then be heated to cure the gum
composition
and form a cured article.
In some embodiments, the mixture may be press cured. Pressing of the
compounded mixture usually is conducted at a temperature sufficient to cure
the mixture
within a desired time under a suitable pressure. In some embodiments, the
temperature is
at least about 95 C, in some embodiments, at least about 150 C. In some
embodiments,
the temperature is not greater than about 230 C, in some embodiments, not
greater than
about 205 C. In some embodiments, the desired time is between about 1 minute
and 15
hours, in some embodiments, between about 5 minutes and 30 minutes. In some
embodiments, a pressure of between about 700 kPa and about 20,600 kPa is
imposed on
the compounded mixture in a mold. The molds first may be coated with a release
agent
and prebaked. The molded vulcanizate is then usually post-cured (e.g., in an
oven) at a
temperature and for a time sufficient to complete the post-curing, usually
between about
150 C and about 300 C, typically at about 232 C, for a period of from about
2 hours to
50 hours or more, generally increasing with the cross-sectional thickness of
the article.
For thick sections, the temperature during the post cure is usually raised
gradually from
-16-
CA 02592041 2007-06-20
WO 2006/068685 PCT/US2005/036224
the lower limit of the range to the desired maximum temperature. The maximum
temperature used is preferably about 300 C, and this value is held for about
4 hours or
more.
The fluoropolymer compositions are useful in production of articles such as 0-
rings, gaskets, tubing, hoses, hose linings, and seals. Such articles are
produced by
molding a compounded formulation of the fluoropolymer composition with various
additives under pressure, curing the article, and then subjecting it to a post-
cure cycle. The
curable compositions formulated without inorganic acid acceptors are
particularly well
suited for applications such as seals and gaskets for manufacturing
semiconductor devices,
and in seals for high temperature automotive uses.
The invention will now be described further by way of the following examples.
EXAMPLES
Test Methods
In the following examples, the indicated results were obtained using the
following
test methods.
Cure rheology tests were run on uncured, compounded samples using a Monsanto
Moving Die Rheometer (MDR) Mode12000 in accordance with ASTM D 5289-93a at
177 C (temperature unless otherwise noted), no pre-heat, 30 minute elapsed
time, and a
0.5 degree arc. Both the minimum torque (ML) and highest torque attained
during a
specified period of time when no plateau or maximum torque was obtained (MH)
were
measured. Also measured were the time for the torque to reach a value equal to
ML +
0.5(MH - ML), (t50), and the time for the torque to reach ML + 0.9(MH - ML),
(t90).
Unless otherwise noted, all parts, percentages, ratios, etc. in the examples
and the
rest of the specification are by weight, and all reagents used in the examples
were
obtained, or are available, from general chemical suppliers such as Sigma-
Aldrich
Company, Saint Louis, Missouri, or Aldrich Chemicals, Milwaukee, Wisconsin; or
may be
synthesized by conventional methods.
FT-IR spectroscopy (Nicolet Magna 560 FT-IR Spectrometer) was used to
determine the percent conversion of nitrile groups using film 0.3 to 0.4 mm
thick. The
mol% of nitrile groups was determined by the following equation
-17-
CA 02592041 2007-06-20
WO 2006/068685 PCT/US2005/036224
Nitrile mol% - 2.62 * nitrile peak height at 2263 cm-1
C- F overtone peak height at 23 59 cm-1
The following abbreviations are used throughout the Examples:
Abbreviation Description
TFE tetrafluoroethylene
PMVE perfluoromethylvinyl ether
MV5CN CF2=CFO(CF2)5CN
HFE-7100 NovecTM Engineered Fluid HFE-7100 commercially available
from 3M Company, St. Paul, MN (swelling agent)
THF tetrahydrofuran
Fluoropolymer A A perfluoroelastomer of 65.7 mol% tetrafluoroethylene (TFE),
33.0 mol% perfluoromethyl perfluorovinyl ether (PMVE) and 1.3
mol% CF2=CFO(CF2)5CN (MV5CN) was prepared by aqueous
emulsion polymerization. The Mooney viscosity (ML 1+10, 121
C) was about 80 (ASTM D-1646).
Curative A See "Curative Preparation" below.
Curative B See "Curative Preparation" below.
urotropin hexamethylene tetramine
Curative Preparation
Curative A: Perfluoroadiponitrile Bisamidine
NH2(NH=)C(CF2)4C(=NH)NH2
A 4 L plastic flask equipped with magnetic stirring was charged with methanol
(188 g, 5.9 mol). Perfluoroadipoyl fluoride (454 g, 1.5 mol; available from
Exfluor
Research Corp. (Austin, Texas)) was added over one hour. A caustic scrubber
was used
for treating the hydrofluoric acid byproduct. Perfluoroadipate (446 g, 1.4
mol) was
isolated by addition of water followed by distillation of the lower
fluorochemical product
phase. A 2 L flask equipped with a mechanical stirrer was charged with the
perfluoroadipate (446 g, 1.4 mol) in methanol, which was reacted with an
excess of
ammonia (54 g, 3.2 mol) to give perfluoroadipoyl amide (385 g, 1.3 mol, after
vacuum
drying). A 3 L flask with a mechanical stirrer was charged with a solution of
the
-18-
CA 02592041 2007-06-20
WO 2006/068685 PCT/US2005/036224
perfluoroadipoyl amide (385 g, 1.3 mol) in dimethylformamide, which was
reacted at
-10 C first with pyridine (508 g, 6.4 mol) followed by trifluoroacetic
anhydride (674 g,
3.2mol). Perfluoroadiponitrile (235 g, 0.9 mol) with a 64 C boiling point was
isolated by
addition of water followed by distillation of the lower fluorochemical product
phase. A 1
L flask equipped with a mechanical stirrer was charged with the
perfluoroadiponitrile (108
g, 0.4 mol) in diethyl ether and reacted at -10 C with ammonia (17 g, 1.0
mol) to give
perfluoroadiponitrile bisamidine (112 g, 0.9 mol, after vacuum drying) having
a melting
point of 132 C. The structure was confirmed by fluorine and proton NMR.
Curative B: Di-acetic acid salt of perfluorotetraethylene oxide dinitrile
bisamidine
CH3COO(")(+)NH3(NH=)C(CF2OCF2)3C(=NH)NH3(+)(")OOCCH3
Fifty-five grams of a 4.7% w/w ammonia in methanol mixture (0.15 mol ammonia)
were added dropwise to a round-bottomed flask containing 73 g of methyl
perfluorotetraethylene oxide dimethyl ester (0.14 mol, 87%; prepared as
described in U.S.
Patent No. 5,488,142) while cooling with an ice bath. The temperature was
maintained at
40 C and titration was continued until the IR absorbance of the methyl ester
carbonyl
disappeared. Sixty-seven grams (0.14 mol) of perfluorotetraethylene oxide
diamide was
recovered after solvent removal (40 C/55 mm Hg, then 40 C/0.1 mm Hg). NMR
analysis
indicated 98% bisamide, 1.4% bisester, and 0.4% methanol.
Sixty-one grams (0.14 mol) of the of the bisamide was dissolved in 80 mL of
THF,
dried over MgSO4, filtered into a 1 L round-bottom flask using three 20 niL
THF washes,
and cooled under nitrogen to -20 C. Fifty-three grams (0.67 mol) of anhydrous
pyridine
was added to the stirred solution. Seventy-one grams (0.34 mol) of
trifluoroacetic
anhydride was added over 70 minutes wliile maintaining the temperature at -5
to -10 C.
The reaction mixture was warmed to ambient temperature over two hours. One
hundred
mL of Freon F-113 (E. I. du Pont de Nemours & Co., Wilmington, Delaware) was
added
and the solution was washed multiple times with saturated brine. A 70% crude
yield was
estimated by gas chromatography. The bisnitrile was purified by shortpath
distillation
(103 to 107 C) and characterized by fluorine NMR.
Twelve grams of the bisnitrile (23 mmol) in 10 mL of HFE 7100 was titrated
with
anhydrous ammonia until no nitrile stretch was observed by IR (2269 cm-1).
Acetic acid
(2.8 g, 46 mmol) was added to the solution and the contents transferred to a
larger round-
-19-
CA 02592041 2007-06-20
WO 2006/068685 PCT/US2005/036224
bottomed flask. Solvents were removed by rotary evaporation to a final weight
of 20.3 g
of the di-acetic acid salt of perfluorotetraethylene oxide dinitrile
bisamidine.
ExMles 1 a - 1 d: Pendant Amidrazone
A 2 L, three-necked, glass flask with condenser and stirrer were charged with
300 g
of Fluoropolymer A, 400 g of HFE-7100, 450 g of methanol, and 6.4 g of 25 wt%
hydrazine in water. After 3 hours of stirring at room temperature, the
reaction was
terminated. The sample was dried for 15 hours at 50 C and then further dried
for 3 hours
under vacuum. The conversion of nitrile groups into amidrazone groups was
monitored
via FT IR measurements at 2264 cm 1 for the -CN absorption and at 1660 (1610 -
1680
cm 1) and 1571 cm 1 for the amidrazone absorption. The FT IR spectrum showed
significant reduction of iiitrile content (0.9 mol% remaining). For Examples
la-1d,
samples were press cured for 12 minutes at the temperatures shown in Table 1.
Example
la was cured without additional curative. Example lb was cured using 2 phr of
Curative
A. Example 1 c was cured with 2 phr of Curative B. Example 1 d was cured with
1 phr
urotropin. The post-cure program was 200 C for 24 hours followed by 300 C
for 8
hours.
Rheology data for these cured samples are presented in Table 1. For each
sample,
FT IR clearly showed a triazine peak at 1556 cni 1.
Example 2: Pendant Amidoxime
A 2-L, three-necked, glass flask with condenser and stirrer were charged with
300
g of Fluoropolymer A, 1000 g of HFE-7100, 800 g of methanol, and 50 g of 50
wt%
hydroxylamine in water. After 6 hours of stirring at 47 C, the reaction was
terminated.
The sample was dried for 15 hours at 50 C and then further dried for another
3 hours
under vacuum. The conversion of nitrile groups into amidoxime groups was
monitored
via FT-IR measurements. The FT-IR spectrum (2264 cm 1) showed no evidence of
the
nitrile groups, and new peaks appeared at 1581 and 1685 cm"1, which belong to
the
expected amidoxime structure. The sample was press cured without additional
curative.
Rheology data is provided in Table 1.
The polymer molded as a crystal clear MDR slug.
-20-
CA 02592041 2007-06-20
WO 2006/068685 PCT/US2005/036224
Example 3: Pendant Amidoxime
A 2 L, three-necked, glass flask with condenser and stirrer were charged with
300
g of Fluoropolymer A, 125 g of HFE-7100, 500 g of methanol and 2.6 g of 50 wt%
hydroxylamine in water. After 20 hours of stirring at 20 C, the reaction was
terminated.
The sample was dried for 15 hours at 80 C and then further dried for 3 hours
under
vacuum. The conversion of nitrile groups into amidoxime groups was monitored
via FT-
IR measurements at 2264 cm"1 for the CN absorption and at 1686 - 1692 cm 1 for
the
amidoxime absorption. The FT-IR spectrum showed significant reduction of
nitrile
content (0.5 mol% remaining).
Table 1
la lb lc ld 2
A B Urotropin
Curative None (2 phr) (2 phr) (1 phr) None
Tem erature 177 C 177 C 188 C 177 C 188 C
ML (N-m) 0.116 0.103 0.068 0.150 0.533
(1.03 in-lb) (0.91 in-lb) (0.60 in-lb) (1.33 in-lb (4.72 in-lb)
MH (N-m) 0.171 0.179 0.107 0.220 0.737
(1.51 in-lb) (1.58 in-lb) (0.95 in-lb (1.95 in-lb (6.52 in-lb)
t50 min) 4.97 6.29 5.65 5.78 4.71
t90 (min) 9.19 10.74 9.96 10.36 8.78
A number of embodiments of the invention have been described. Nevertheless, it
will be understood that various modifications may be made without departing
from the
spirit and scope of the invention.
-21-
